Cited by 396Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Open access

Spring, Laura M., Gupta, Arjun, Reynolds, Kerry L., Gadd, Michele A., Ellisen, Leif W., Isakoff, Steven J., Moy, Beverly, Bardia, Aditya·2016·JAMA Oncology

DOI 10.1001/jamaoncol.2016.1897PMC PMC5738656

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Estrogen receptor-positive (ER+) tumors of the breast are generally highly responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant treatment for ER+ breast cancer, the role of endocrine therapy in the neoadjuvant setting is unclear. OBJECTIVE: To evaluate the effect of neoadjuvant endocrine therapy (NET) on the response rate and the rate of breast conservation surgery (BCS) for ER+ breast cancer. DATA SOURCES: Based on PRISMA guidelines, a librarian-led search of PubMed and Ovid MEDLINE was performed to identify eligible trials published from inception to May 15, 2015. The search was performed in May 2015. STUDY SELECTION: Inclusion criteria were prospective, randomized, neoadjuvant clinical trials that reported response rates with at least 1 arm incorporating NET (n = 20). Two authors independently analyzed the studies for inclusion. DATA EXTRACTION AND SYNTHESIS: Pooled odds ratios (ORs), 95% CIs, and P values were estimated for end points using the fixed- and random-effects statistical model. RESULTS: The analysis included 20 studies with 3490 unique patients. Compared with combination chemotherapy, NET as monotherapy with aromatase inhibitors had a similar clinical response rate (OR, 1.08; 95% CI, 0.50-2.35; P = .85; n = 378), radiological response rate (OR, 1.38; 95% CI, 0.92-2.07; P = .12; n = 378), and BCS rate (OR, 0.65; 95% CI, 0.41-1.03; P = .07; n = 334) but with lower toxicity. Aromatase inhibitors were associated with a significantly higher clinical response rate (OR, 1.69; 95% CI, 1.36-2.10; P < .001; n = 1352), radiological response rate (OR, 1.49; 95% CI, 1.18-1.89; P < .001; n = 1418), and BCS rate (OR, 1.62; 95% CI, 1.24-2.12; P < .001; n = 918) compared with tamoxifen. Dual combination therapy with growth factor pathway inhibitors was associated with a higher radiological response rate (OR, 1.59; 95% CI, 1.04-2.43; P = .03; n = 355), but not clinical response rate (OR, 0.76; 95% CI, 0.54-1.07; P = .11; n = 537), compared with endocrine monotherapy. The incidence of pathologic complete response was low (<10%). CONCLUSIONS AND RELEVANCE: Neoadjuvant endocrine therapy, even as monotherapy, is associated with similar response rates as neoadjuvant combination chemotherapy but with significantly lower toxicity, suggesting that NET needs to be reconsidered as a potential option in the appropriate setting. Additional research is needed to develop rational NET combinations and predictive biomarkers to personalize the optimal neoadjuvant strategy for ER+ breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.1897

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900

Show all 60 references

Research works printed but not linked: 1

[61]Ma CX Gao F Northfelt D A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2−) breast cancer (BC) Presented at: San Antonio Breast Cancer Symposium December 11, 2015 San Antonio, TX Abstract S6-05

Sorted by citations

Items 101–200 of 396

Endocrine therapy resistance: what we know and future directions
Musheyev, D., & Alayev, A. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00096 · Cited by 21
Pre-operative Endocrine Therapy
Arthur, L. M., Turnbull, A., Khan, L. R., & Dixon, J. M. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0255-6 · Cited by 20
Recent advances in neoadjuvant therapy for breast cancer
Potter, D. A., Herrera-Ponzanelli, C., Ugarte, D. H., Castillo, R., Hernández-Cruz, I. A., Arrieta, V. A., Franklin, M. J., & Yee, D. (2021) · Faculty Reviews · doi:10.12703/r/10-2 · Cited by 21
Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells
Pandey, V., Zhang, M., Chong, Q.-Y., You, M., Raquib, A. R., Pandey, A. K., Liu, D., Liu, L., Ma, L., Jha, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20461 · Cited by 19
Current controversies in the use of Oncotype DX in early breast cancer
Giachetti, P. P. M. B., Schianca, A. C., Trapani, D., Marra, A., Toss, A., Marchiò, C., Dieci, M. V., Gentilini, O., Criscitiello, C., Kalinsky, K. M., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102887 · Cited by 18
Covid-19 related oncologist’s concerns about breast cancer treatment delays and physician well-being (the CROWN study)
Yao, K. A., Attai, D. J., Bleicher, R. J., Kuchta, K. M., Moran, M. S., Boughey, J. C., Wilke, L. G., Dietz, J. R., Stevens, R. E., Pesce, C. E., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06101-1 · Cited by 18
The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study
Martí, C., Yébenes, L., Oliver, J. M., Moreno, E., Frías, L., Berjón, A., Loayza, A., Meléndez, M., Roca, M. J., Chicote, V. C., et al. (2022) · Current Oncology · doi:10.3390/curroncol29040179 · Cited by 18
89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study
Linders, D. G. J., Deken, M. M., van Dam, M. A., Wasser, M. N. J. M., Voormolen, E. M. C., Kroep, J. R., van Dongen, G. A. M. S., Vugts, D. J., Oosterkamp, H. M., Straver, M. E., et al. (2023) · Cancers · doi:10.3390/cancers15204980 · Cited by 18
Breast surgery after neoadjuvant systemic therapy
Pawloski, K. R., & Barrio, A. V. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-23-50 · Cited by 18
Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma
Resende, U., Cabello, C., Ramalho, S., & Zeferino, L. C. (2018) · Oncology · doi:10.1159/000489785 · Cited by 18
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
Jones, E. F., Hathi, D., Freimanis, R. I., Mukhtar, R. A., Chien, A. J., Esserman, L. J., Veer, L. J. V., Joe, B. N., & Hylton, N. M. (2020) · Cancers · doi:10.3390/cancers12061511 · Cited by 19
Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
Reis, J. S., Lindstrøm, J. C., Boavida, J., Gjesdal, K., Park, D., Bahrami, N., Seyedzadeh, M., Melles, A. W., Sauer, T., Geisler, J., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05852-7 · Cited by 18
Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma
Hills, N., Leslie, M., Davis, R. B., Crowell, M., Kameyama, H., Rui, H., Chervoneva, I., Dooley, W. C., & Tanaka, T. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09747-9 · Cited by 18
A review of studies on omitting surgery after neoadjuvant chemotherapy in breast cancer.
Feng, K., Jia, Z., Liu, G., Xing, Z., Li, J., Li, J., Ren, F., Wu, J., Wang, W., Wang, J., et al. (2022) · PubMed Central · Cited by 18
Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model
Feng, X., Shi, Y., Wu, M., Cui, G., Du, Y., Yang, J., Xu, Y., Wang, W., & Liu, F. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-01971-5 · Cited by 17
The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making
Whitehead, I., Irwin, G. W., Bannon, F. J., Coles, C. E., Copson, E., Cutress, R., Dave, R., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07757-6 · Cited by 17
Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment
Takeshita, T., Oshino, T., Tokumaru, Y., Oshi, M., Patel, A. P., Tian, W., Hatanaka, Y., Hatanaka, K. C., Yan, L., & Takabe, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.865024 · Cited by 17
Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy
Brzezinska, M., & Dixon, J. M. (2018) · Gland Surgery · doi:10.21037/gs.2018.08.04 · Cited by 17
From Experiment to Theory: What Can We Learn from Growth Curves?
Kareva, I., & Karev, G. P. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-017-0347-5 · Cited by 16
Breast Cancer Management Guidelines During COVID-19 Pandemic
Manoj Gowda, S., Kabeer, K. K., Jafferbhoy, S. F., Marla, S., Soumian, S., Misra, V., Narayanan, S., & Brunt, A. M. (2020) · Indian Journal of Surgery · doi:10.1007/s12262-020-02466-7 · Cited by 16
Development of novel agents for the treatment of early estrogen receptor positive breast cancer
Elliott, M. J., & Cescon, D. W. (2021) · The Breast · doi:10.1016/j.breast.2021.11.007 · Cited by 15
Preoperative Systemic Therapy for Breast Cancer
Kodali, A., & Gadi, V. K. (2022) · Surgical Clinics of North America · doi:10.1016/j.suc.2022.08.017 · Cited by 15
Adjuvant and Neoadjuvant Therapy for Breast Cancer: A Systematic Review
Qari, A. S., Mowais, A. H., Alharbi, S. M., Almuayrifi, M. J., Asiri, A. A. A., Alwatid, S. A., Aljohani, A. A., Alanazi, R. M., & Althoubaity, F. (2024) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2024.2023-12-16 · Cited by 15
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry
Smith, B. L., Nguyen, A., Korotkin, J. E., Kelly, B. N., Specht, M. C., Spring, L. M., Moy, B., Isakoff, S. J., & Gadd, M. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05792-2 · Cited by 15
Self-citation
A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
Oshi, M., Gandhi, S., Angarita, F. A., Kim, T. H., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2021) · PubMed Central · Cited by 15
Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
Sato, N., Masuda, N., Morimoto, T., Ueno, T., Kanbayashi, C., Kaneko, K., Yasojima, H., Saji, S., Sasano, H., Morita, S., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1600 · Cited by 15
Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy
Baxter, D. E., Kim, B., Hanby, A. M., Verghese, E. T., Sims, A. H., & Hughes, T. A. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.002 · Cited by 14
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Vaklavas, C., Roberts, B. S., Varley, K. E., Lin, N., Liu, M., Rugo, H. S., Puhalla, S., Nanda, R., Storniolo, A. M., Carey, L., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01258-x · Cited by 14
ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
Gong, Y., Hu, N., Ma, L., Li, W., Cheng, X. C., Zhang, Y., Zhu, Y., Yang, Y., Peng, X., Zou, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.571517 · Cited by 14
Locally Advanced Breast Cancer
da Costa, R. B., Hansen, N. M., & Gradishar, W. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00063-5 · Cited by 13
Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis
Guan, Y., Shen, G., Fang, Q., Xin, Y., Huo, X., Li, J., Zhao, F., Ren, D., Liu, Z., Li, Z., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00814-3 · Cited by 13
Barriers to timely surgery for breast cancer in Rwanda
Schleimer, L. E., Dusengimana, J. M. V., Butonzi, J., Kigonya, C., Natarajan, A., Umwizerwa, A., O’Neil, D. S., Costas‐Chavarri, A., Majyambere, J. P., Shulman, L. N., et al. (2019) · Surgery · doi:10.1016/j.surg.2019.06.021 · Cited by 13
Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease
Hammond, J. B., Parnall, T. H., Scott, D. W., Kosiorek, H., Pockaj, B. A., Ernst, B. J., Northfelt, D., McCullough, A. E., Ocal, I. T., & Cronin, P. A. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26047 · Cited by 13
Ten-Year Oncologic Outcomes in T1-3N1 Breast Cancer After Targeted Axillary Sampling: A Retrospective Study
Lee, J., Jung, J. H., Kim, W. W., Kang, B., Keum, H., Chae, Y. S., Lee, S. J., Park, J. Y., Park, J. Y., Jung, T., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13191-2 · Cited by 13
COVID-19 Pandemic: Changes in Care for a Community Academic Breast Center and Patient Perception of Those Changes
Kennard, K., Williams, A. D., Goldblatt, L. G., Buckley, M. E., Bruce, L., Larson, S. L., Carter, W. B., Lamb, E. P., Carp, N. Z., Sizer, L. M., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09583-3 · Cited by 13
Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis
Zhang, T., Feng, F., Yao, Y., Qi, L., Tian, J., Zhou, C., Dong, S., Wang, X., & Sun, C. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28068 · Cited by 13
Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer
Hage, A. N., Capriccioso, C., Brennan, J. R., Heiden, B. T., Zheutlin, A. R., & Sabel, M. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24721 · Cited by 12
Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
Dey, N., Aske, J. C., & De, P. K. R. (2021) · Cancers · doi:10.3390/cancers13030458 · Cited by 12
Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity‐score matched cohort study
Zhou, W., Jiang, Y., Xu, Y., Wang, Y., Ma, X., Zhou, L., Lin, Y., Wang, Y., Wu, Z., Li, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33919 · Cited by 12
Neoadjuvant Therapy in Breast Cancer
Troxell, M. L., & Gupta, T. (2022) · Surgical pathology clinics · doi:10.1016/j.path.2021.11.004 · Cited by 12
Effects of Lean Thinking and Emerging Technologies on Breast Cancer Patients' Therapeutic Process During COVID-19 Pandemic: A Case-Control Matched Study
Pellini, F., Filippo, G. D., Mirandola, S., Deguidi, G., Filippi, E., & Pollini, G. P. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.582980 · Cited by 12
Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy
Han, M., Li, J., Wu, S., Wu, C., Yu, Y., & Liu, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5207 · Cited by 11
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer
Martínez-Pérez, C., Turnbull, A., Kay, C., & Dixon, J. M. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2162043 · Cited by 11
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
López-Velazco, J. I., Manzano, S., Otaño, M., Elorriaga, K., Bultó, N., Herrero, J. J., Lahuerta, A., Segur, V., Álvarez, I., Caffarel, M. M., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-023-01756-8 · Cited by 11
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
Chen, L., Wu, W., Liang, F., Liu, G., Yu, K., Wu, J., Di, G., Fan, L., Wang, Z., Li, J., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.12649 · Cited by 11
Preparing for the Renaissance: Treating Breast Cancer during the COVID-19 Pandemic and Planning for a Safe Re-Emergence to Routine Surgical Care within a Universal Health Care System
Berger‐Richardson, D., Ko, G., & Hong, N. J. L. (2020) · Current Oncology · doi:10.3747/co.27.6699 · Cited by 11
Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
Ragusi, M. A. A., Loo, C. E., van der Velden, B. H. M., Wesseling, J., Linn, S. C., Beets‐Tan, R. G. H., Elias, S. G., & Gilhuijs, K. G. A. (2020) · European Radiology · doi:10.1007/s00330-020-07058-3 · Cited by 11
Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study
Wang, X., Fan, Z., Wang, X., He, Y., Liu, Y., Wang, X., Zhang, B., Jiang, Z., Wang, T., Yu, Z., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06686-1 · Cited by 11
Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer
Provenzano, E., & Shaaban, A. M. (2022) · Histopathology · doi:10.1111/his.14771 · Cited by 11
Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
Reinert, T., Ramalho, S., Gonçalves, R., Barrios, C., Graudenz, M. S., & Bines, J. (2016) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0036-1597579 · Cited by 11
A systematic review of generic and breast cancer specific life expectancy models in the elderly
Thomas, R., Pieri, A., & Cain, H. J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.06.014 · Cited by 11
Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice
Badr, N. M., Spooner, D. A., Steven, J., Stevens, A., & Shaaban, A. M. (2021) · Histopathology · doi:10.1111/his.14331 · Cited by 11
Survival comparison between postoperative and preoperative radiotherapy for stage I–III non-inflammatory breast cancer
Zhang, Y., Xu, Z., Chen, H., Sun, X., & Zhang, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-18251-3 · Cited by 11
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Taylor, C., Meisel, J. L., Foreman, A. J., Russell, C. A., Bandyopadhyay, D., Deng, X., Floyd, L., Zelnak, A. B., Bear, H. D., & O'Regan, R. M. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06890-7 · Cited by 10
Neoadjuvant chemotherapy in non-metastatic breast cancer: The surgeon's perspective
Ofri, A., Elstner, K., Mann, G. B., Kumar, S., & Warrier, S. (2023) · The Surgeon · doi:10.1016/j.surge.2023.04.001 · Cited by 11
Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
Goldbach, M. M., Burkbauer, L., Bharani, T., Williams, A. D., Keele, L. J., Rothman, J. D., Jankowitz, R. C., & Tchou, J. C. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10287-5 · Cited by 10
Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data
Engel, J., Eckel, R., Schrodi, S., Halfter, K., Schubert-Fritschle, G., & Hölzel, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04369-4 · Cited by 11
Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art
Saux, O. L., Lounici, Y., Wajda, P., Ghamry-Barrin, S., Caux, C., Dubois, B., & Ray-Coquard, I. L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103172 · Cited by 10
Acupuncture-related techniques for postoperative cognitive complications: a systemic review and meta-analysis
Zhang, J., Cairen, Z., Shi, L., Zhang, M., Yang, M., Wang, Y., & Lu, Z. (2023) · Perioperative Medicine · doi:10.1186/s13741-023-00303-5 · Cited by 9
Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer
Hirmas, N., Holtschmidt, J., & Loibl, S. (2024) · Cancers · doi:10.3390/cancers16183236 · Cited by 10
Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer
Li, C., Dai, H., Guo, X., Zhou, L., & Jiang, M. (2025) · iScience · doi:10.1016/j.isci.2025.111759 · Cited by 9
Prognostic significance of receptor conversion following neoadjuvant therapy in breast cancer: a systematic review & meta-analysis
Dowling, G. P., Daly, G. R., Hehir, C. M., Alrawashdeh, M. M., Calpin, G. G., Almasri, S., Toomey, S., Young, L. S., Hennessey, B. T., & Hill, A. D. K. (2025) · The Breast · doi:10.1016/j.breast.2025.104516 · Cited by 9
Histopathology during the COVID-19 pandemic: resilience through adaptation and innovation
Bracey, T. S., Arif, S., Ralte, A. M., Shaaban, A. M., & Ganesan, R. (2020) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2020.12.003 · Cited by 9
Neoadjuvant systemic therapy for breast cancer
Zaborowski, A. M., & Wong, S. M. (2023) · British journal of surgery · doi:10.1093/bjs/znad103 · Cited by 9
Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial
Alsaleh, K. A., Zahwahry, H. A., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel‐Razeq, H., et al. (2021) · JCO Global Oncology · doi:10.1200/go.20.00575 · Cited by 9
Controversies in Breast Cancer Surgery
Gutnik, L. A., & Fayanju, O. M. (2021) · Surgical Clinics of North America · doi:10.1016/j.suc.2021.06.002 · Cited by 9
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Zhao, H., Li, D., Li, Q., Zhang, B., Xiao, C., Zhao, Y., Ge, J., Yu, Y., Jia, Y., Guo, X., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae033 · Cited by 8
Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers
Miligy, I. M., Badr, N. M., Stevens, A., Spooner, D. A., Awasthi, R., Mir, Y., Khurana, A., Sharma, V. S., Chandaran, U., Rakha, E. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137381 · Cited by 8
CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2− breast cancer
Fang, D., Lin, J., Wang, J., Nong, Q., Tao, S., Lu, B., Yu, Y., Peng, H. Y., Tian, Y., Su, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1662004 · Cited by 9
Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer
Koenig, J. L., Kozak, M. M., Sabolch, A. N., Horst, K. C., Tsai, J., Wapnir, I., & Pollom, E. L. (2019) · Cureus · doi:10.7759/cureus.5748 · Cited by 8
Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients
Boland, M. R., Ryan, É. J., Nugent, T., Gilroy, D., Kelly, M. E., Kennedy, J., Maguire, A. A., Al-Azawi, D., Boyle, T. J., & Connolly, E. M. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26096 · Cited by 8
Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
Loo, M., Andour, L., van Heesewijk, A. E., Oosterkamp, H. M., Liefers, G., & Straver, M. E. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07222-5 · Cited by 8
A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
Magno, E., & Bussard, K. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063407 · Cited by 10
Surgical outcomes of neoadjuvant endocrine treatment in early breast cancer: meta-analysis
Brett, B., Savva, C., Mirshekar-Syahkal, B., Hill, M., Douek, M., Copson, E., & Cutress, R. (2024) · BJS Open · doi:10.1093/bjsopen/zrae100 · Cited by 8
CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?
Brandão, M., & Ignatiadis, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy456 · Cited by 8
Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer
Payne, J. B., Flowers, C. R., & Allen, P. B. (2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0494 · Cited by 8
Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer
Jung, S. U., Jung, M.-J., Choi, J. H., & Jeon, C. W. (2021) · Medicine · doi:10.1097/md.0000000000025175 · Cited by 8
Regional Nodal Management After Preoperative Systemic Therapy
Singer, L., Weiss, A. C., Bellon, J. R., & King, T. A. (2022) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2022.01.003 · Cited by 8
Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
Jacobs, F., Gaudio, M., Benvenuti, C., Sanctis, R. D., Santoro, A., & Zambelli, A. (2022) · Cancers · doi:10.3390/cancers15010148 · Cited by 8
Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data
Qiu, J., Zheng, Y., Qian, D., Guan, D., Zheng, Q., Xu, Y., Ju, S., Meng, X., & Tang, H. (2022) · Journal of Oncology · doi:10.1155/2022/6972703 · Cited by 8
Early breast cancer: concept and therapeutic review
Bastos, M. C. S., de Almeida, A. P., Bagnoli, F., & de Oliveira, V. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023s114 · Cited by 12
Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy
Artzy‐Randrup, Y., Epstein, T., Brown, J. S., Costa, R. L. B., Czerniecki, B. J., & Gatenby, R. A. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00230-y · Cited by 8
Prolonged time to breast cancer surgery and the risk of metastasis: an explorative simulation analysis using epidemiological data from Germany and the USA
Hölzel, D., Schlesinger‐Raab, A., Schubert-Fritschle, G., & Halfter, K. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07630-9 · Cited by 7
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
Knudsen, E. S., Witkiewicz, A. K., & Kabraji, S. K. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01431-5 · Cited by 8
Impact of the COVID-19 pandemic on breast surgery and breast reconstruction in a Japanese university hospital setting
Shibata, D., Kawate, T., Komiya, T., Nakamura, I., Ishikawa, T., & Matsumura, H. (2022) · Archives of Plastic Surgery · doi:10.5999/aps.2021.01438 · Cited by 7
Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
Matikas, A., Foukakis, T., Michalakis, I., & Georgoulias, V. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1288105 · Cited by 7
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
Yao, L., Wang, M., Wang, M., Yu, X., Guo, J., Sun, T. C., Li, X., & Xu, Y. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i15.1937 · Cited by 7
Incidence of Metastatic Prostate Cancer On the Rise
Broderick, J. M. (2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0460 · Cited by 8
Predictive and prognostic relevance of immunohistochemical testing of estrogen and progesterone receptors in breast cancer in South East Nigeria: A review of 417 cases
Nzegwu, M. A., Uzoigwe, J. C., Omotowo, B. I., Ugochukwu, A. I., Ozumba, B. C., Sule, E. A., Ezeome, E., Olusina, D. B., Okafor, O. C., Nzegwu, V., et al. (2021) · Rare Tumors · doi:10.1177/20363613211006338 · Cited by 7
ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer
Karsono, R., Haryono, S. J., Karsono, B., Harahap, W. A., Pratiwi, Y., & Aryandono, T. (2021) · BMC Cancer · doi:10.1186/s12885-021-09083-x · Cited by 7
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis
Zheng, C., & Chagpar, A. B. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06510-w · Cited by 8
“How can a woman live without having a breast?”: challenges related to mastectomy in Ethiopia
Wondimagegnehu, A., Teferra, S., Assefa, M., Zebrack, B., Addissie, A., & Kantelhardt, E. J. (2024) · BMC Cancer · doi:10.1186/s12885-023-11801-6 · Cited by 7
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
Sato, N., Masuda, N., Morimoto, T., Ueno, T., Kanbayashi, C., Kaneko, K., Yasojima, H., Saji, S., Sasano, H., Morita, S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2423 · Cited by 7
Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer
Jackisch, C. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30500-5 · Cited by 7
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
Zotano, Á. G., Pérez-García, J. M., Ruíz‐Borrego, M., Bermejo, B., Gil‐Gil, M., de la Haba, J., Alba, E., Quiroga, V., Carañana, V., Urruticoechea, A., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103733 · Cited by 6
An Overview of the Importance of Neoadjuvant Systemic Therapy for Breast Cancer Patients: From the Society of Surgical Oncology and the American Society of Breast Surgeons
Weiss, A., Agnese, D. M., Al‐Hilli, Z., Cabıoğlu, N., Farr, D., Kantor, O., Obeng‐Gyasi, S., & Wilke, L. G. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17405-7 · Cited by 6
Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systematic review and meta-analysis
Ergün, Y., Uçar, G., & Akagündüz, B. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2203485 · Cited by 6
Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
Chen, R., Yu, Y., Zhang, J., Song, C., & Wang, C. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2350105 · Cited by 6
Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution
An, S. J., Thai, C., Ismail, S., Agala, C. B., Hoang, V., Feeney, T., Lillie, M., Wheless, A., Selfridge, J. M., Ollila, D. W., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16059-1 · Cited by 6
Neoadjuvant Radiotherapy and Endocrine Therapy for Oestrogen Receptor Positive Breast Cancers: The Neo-RT Feasibility Study
Lightowlers, S., Machin, A., Woitek, R., Provenzano, E., Allajbeu, I., Sarakbi, W. A., Demiris, N., Forouhi, P., Gilbert, F. J., Kirby, A. M., et al. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.103669 · Cited by 6

Authors: Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A.
Affiliations: Harvard University (US)
The University of Texas Southwestern Medical Center (US)
Corresponding author: Bardia, Aditya
ORCID: Spring, Laura M.
Gupta, Arjun
Reynolds, Kerry L.
Ellisen, Leif W.
Isakoff, Steven J.
Moy, Beverly
Bardia, Aditya
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2016-11-01
Volume: 2
Issue: 11
Pages: 1477
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2016.1897
PMC: PMC5738656
OpenAlex: W2467606258
Cited by: 396
References: 60
Citations by year: 2026: 28 · 2025: 52 · 2024: 48 · 2023: 36 · 2022: 48 · 2021: 56 · 2020: 63 · 2019: 26 · 2018: 13 · 2017: 18 · 2016: 8
FWCI: 9.03
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001102)
National Cancer Institute (K12CA087723, T32CA071345)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: neoadjuvant endocrine therapy, estrogen receptor-positive breast cancer, aromatase inhibitors, breast-conserving surgery, clinical response rate, combination chemotherapy, treatment toxicity, randomized controlled trials meta-analysis
MeSH terms: Breast Neoplasms, Female, Humans, Receptors, Estrogen, Randomized Controlled Trials as Topic, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks